MBIO: the cashflow

MyFinsight

For the quarter ending 2025-09-30.

Unit: Thousand (K) dollars (except for numbers of shares and EPS)

Cash Flow	2025-09-30	2025-06-30
Net loss	-1,383	-915
Issuance of common shares - equity fee on equity offerings to fortress biotech	395	216
Stock-based compensation expenses	106	83
Depreciation expense	34	34
Amortization of operating lease right-of-use assets	7	7
Settlement of payables	1,373	796
Loss on disposal of property and equipment	0	0
Asset impairment	0	0
Gain on lease termination	394	394
Prepaid expenses and other assets	-40	-28
Other receivables	-435	-435
Accounts payable and accrued expenses	-1,202	-1,190
Payable and accrued expenses - related party	-138	-163
Lease liabilities	73	73
Net cash used in operating activities	-3,546	-2,728
Proceeds from the sale of property and equipment	1,165	1,165
Net cash from investing activities	1,165	1,165
Proceeds from issuance of common shares, net of offering costs - equity offering	6,782	6,782
Proceeds from issuance of common shares, net of offering costs - at-the-market offering	599	599
Proceeds from warrant exercises	7,145	0
Proceeds from issuance of common shares under espp	0	0
Net cash provided by financing activities	14,526	7,381
Net change in cash, cash equivalents and restricted cash	12,145	5,818
Cash and cash equivalents at beginning of period	6,839	-
Cash and cash equivalents at end of period	18,984	-

Unit: Thousand (K) dollars (except for numbers of shares and EPS)

MBIO: the cashflow